PDT Partners LLC Sells 128,512 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

PDT Partners LLC trimmed its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 70.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,291 shares of the company's stock after selling 128,512 shares during the quarter. PDT Partners LLC owned 0.06% of Verve Therapeutics worth $301,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in Verve Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock worth $101,000 after buying an additional 1,676 shares during the last quarter. Rhumbline Advisers raised its holdings in Verve Therapeutics by 1.9% in the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock worth $627,000 after purchasing an additional 2,093 shares during the period. Arizona State Retirement System grew its holdings in shares of Verve Therapeutics by 15.8% in the 4th quarter. Arizona State Retirement System now owns 19,593 shares of the company's stock valued at $111,000 after buying an additional 2,669 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Verve Therapeutics by 5.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company's stock valued at $313,000 after purchasing an additional 2,742 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Verve Therapeutics by 5.7% in the fourth quarter. Invesco Ltd. now owns 57,140 shares of the company's stock worth $322,000 after purchasing an additional 3,080 shares in the last quarter. Institutional investors and hedge funds own 97.11% of the company's stock.

Verve Therapeutics Trading Up 8.2 %

Verve Therapeutics stock traded up $0.35 during midday trading on Thursday, reaching $4.57. The stock had a trading volume of 1,801,039 shares, compared to its average volume of 1,810,665. The company has a fifty day moving average price of $5.06 and a two-hundred day moving average price of $5.93. Verve Therapeutics, Inc. has a 12 month low of $2.86 and a 12 month high of $9.31. The company has a market capitalization of $406.94 million, a P/E ratio of -1.85 and a beta of 1.82.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. On average, equities research analysts predict that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VERV has been the topic of several recent analyst reports. Cantor Fitzgerald raised Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Guggenheim increased their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Royal Bank of Canada reduced their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. William Blair reaffirmed an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their price objective on Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $25.75.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.